Significant events during the first quarter- Net sales increased by 9% (20% adjusted for currency changes) to
SEK 171 m (158). -
EBITDA margin was 28% (19%).
-
First deliveries related to the Pan-European agreement with
Perrigo , which includes the launch of Probi's ClinBac™ concept in 14 European countries. -
Strategic partnership with the Chinese pharmaceutical company
China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade) a wholly owned subsidiary of China National Pharmaceutical Group Corporation (Sinopharm) for the launch of three of Probi's ClinBac™ concepts in China . -
New bone health study in collaboration with
La Trobe University in Australia to investigate the effects of Probi® Osteo on Australian women.
CEO Comments
A good start to 2021
We started the year with good growth of 9% and reached net sales of
The
Particularly pleasing this quarter was the performance in the EMEA region, where net sales increased by 19%. The region therefore reported its strongest quarter ever. Here we can see the clear effects in that we have succeeded in building new customer relationships that strengthen our position in the region. During the quarter, we delivered the first orders to
The APAC region also recovered after a weak second half of 2020 and net sales increased by 5%. Our new team in the region has been established and we have high hopes that the region will grow again. During the quarter, we entered into a partnership with one of
After a 2020 with pandemic-related challenges to initiate clinical studies, we have now been able to resume a high level of activity in research and development. We intend to increase our investments in R&D during the year and have, among others, started a study in collaboration with
Last year, the fluctuation between quarters increased as a consequence of the uncertainty following the outbreak of Covid-19. We expect a continued relatively high fluctuation between quarters this year as well. Underlying demand is good and according to industry statistics, continued global growth for probiotic products is expected. From
After a year of the pandemic, interest in self-care may never have been greater than it is now. At the same time, we want to return to a more normal situation as soon as possible. I am convinced that what we have seen over the past year has created a genuinely increased interest in health products and that
Tom Rönnlund
CEO
Invitation to teleconference
Contact
Tom Rönnlund, CEO, Telefon: +46 (0)46 286 89 40, E-mail: trd@probi.com
This information is information that
https://news.cision.com/probi/r/q1-2021--good-growth-in-the-first-quarter,c3331639
https://mb.cision.com/Main/1556/3331639/1406020.pdf
(c) 2021 Cision. All rights reserved., source